BioInvent International Overview

  • Year Founded
  • 1996

Year Founded

  • Status
  • Public

  • Employees
  • 107

Employees

  • Stock Symbol
  • BINV

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $0.29
  • (As of Friday Closing)

BioInvent International General Information

Description

BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Ideon Science Park
  • Ideongatan 1
  • 223 70 Lund
  • Sweden
+46 046-286
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
STO
Vertical(s)
Corporate Office
  • Ideon Science Park
  • Ideongatan 1
  • 223 70 Lund
  • Sweden
+46 046-286

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BioInvent International Stock Performance

As of 13-Nov-2026, BioInvent International’s stock price is $0.29. Its current market cap is $19.1M with 65.8M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.29 $0.29 $0.19 - $3.75 $19.1M 65.8M 377K -$0.79

BioInvent International Financials Summary

As of 30-Sep-2026, BioInvent International has a trailing 12-month revenue of $4.26M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 119,132 136,610 145,405 11,517
Revenue 4,255 23,054 4,225 6,723
EBITDA (49,840) (33,798) (42,689) (33,945)
Net Income (51,812) (33,880) (40,599) (31,075)
Total Assets 30,817 72,942 89,657 140,103
Total Debt 1,933 927 1,578 2,326
Public Fundamental Data provided by Morningstar, Inc. disclaimer

BioInvent International Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore BioInvent International‘s full profile, request access.

Request a free trial

BioInvent International Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immun
Drug Discovery
Lund, Sweden
107 As of 2026

Cambridge, United Kingdom
 

Redwood City, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BioInvent International Competitors (31)

One of BioInvent International’s 31 competitors is Sareum Holdings, a Corporation company based in Cambridge, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sareum Holdings Corporation Cambridge, United Kingdom
Coherus Oncology Formerly VC-backed Redwood City, CA
Abliva Formerly VC-backed Lund, Sweden
Bristol-Myers Squibb Corporation Princeton, NJ
Active Biotech Corporation Lund, Sweden
You’re viewing 5 of 31 competitors. Get the full list »

BioInvent International Patents

BioInvent International Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026082770-A1 Antibodies against domain 4 of icam-1 and uses thereof Pending 16-Oct-2024
EP-4537337-A1 Methods of isolating anti-ligands Pending 13-Jun-2022
US-20260018241-A1 Methods of isolating anti-ligands Pending 13-Jun-2022
WO-2023242125-A1 Methods of isolating anti-ligands Inactive 13-Jun-2022
WO-2023242125-A8 Methods of isolating anti-ligands Inactive 13-Jun-2022 G16B15/30
To view BioInvent International’s complete patent history, request access »

BioInvent International Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioInvent International Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore BioInvent International‘s full profile, request access.

Request a free trial

BioInvent International Investments (3)

BioInvent International’s most recent deal was a Corporate Asset Purchase with ThromboGenics (TB-403 rights). The deal was made on 01-Jan-2017.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ThromboGenics (TB-403 rights) 01-Jan-2017 Corporate Asset Purchase Buildings and Property
ThromboGenics (TB-403 rights) 05-Jun-2012 Corporate Asset Purchase Buildings and Property
Cartela (Rights to Develop New Drug to Treat Osteoarthritis) 16-Oct-2003 Corporate Asset Purchase Buildings and Property
To view BioInvent International’s complete investments history, request access »

BioInvent International ESG

Risk Overview

Risk Rating

Updated November, 30, 2025

27.85 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,271

Rank

Percentile

Pharmaceuticals

Industry

of 908

Rank

Percentile

Biotechnology

Subindustry

of 434

Rank

Percentile

To view BioInvent International’s complete esg history, request access »

BioInvent International FAQs

  • When was BioInvent International founded?

    BioInvent International was founded in 1996.

  • Where is BioInvent International headquartered?

    BioInvent International is headquartered in Lund, Sweden.

  • What is the size of BioInvent International?

    BioInvent International has 107 total employees.

  • What industry is BioInvent International in?

    BioInvent International’s primary industry is Drug Discovery.

  • Is BioInvent International a private or public company?

    BioInvent International is a Public company.

  • What is BioInvent International’s stock symbol?

    The ticker symbol for BioInvent International is BINV.

  • What is the current stock price of BioInvent International?

    As of 13-Nov-2026 the stock price of BioInvent International is $0.29.

  • What is the current market cap of BioInvent International?

    The current market capitalization of BioInvent International is $19.1M.

  • What is BioInvent International’s current revenue?

    The trailing twelve month revenue for BioInvent International is $4.26M.

  • Who are BioInvent International’s competitors?

    Sareum Holdings, Coherus Oncology, Abliva, Bristol-Myers Squibb, and Active Biotech are some of the 31 competitors of BioInvent International.

  • What is BioInvent International’s annual earnings per share (EPS)?

    BioInvent International’s EPS for 12 months was -$0.79.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process